18F-DCFPyL PET/CT in Castration-Resistant Prostate Cancer (CRPC): Imaging results prior to and following abiraterone or enzalutemide therapy
Bibliographic record
Abstract
1469 Objectives: To evaluate 18F-DCFPyL PET/CT as a non-invasive imaging biomarker in men with CRPC. Methods: 10 men with CRPC had 18F-DCFPyL PET/CT at baseline and after 9-14 weeks of abiraterone or enzalutemide therapy. Standard imaging (bone scan and CT) was done at baseline, after appox. 3 and 6 months of therapy. Disease extent, intra-patient tumor maximum standardized uptake value (SUVmax), therapy response by PSA and time on treatment were recorded. Men were followed for at least 12 months after enrolment. Results: Of 10 men, all had 18F-DCFPyL-avid disease. Five men with widespread disease were on treatment for 548, 399, 279, 209 and 186 days and had SUVmax 80.0, 32.4, 47.8, 19.6 and 42.7. Two men with oligometastatic disease (less than or equal to 5 lesions) were on treatment for 358 and 343 days and had SUVmax 29.7 and 5.3. The remaining 3 men (more than 5 lesions but not widespread) were on treatment for 420, 383 and 214 days and had SUVmax 17.9, 27.4 and 8.1. All men had 18F-DCFPyL-avid disease at baseline and follow-up. Further, the majority of disease sites increased in intensity on follow-up, although in several cases there were mixed interval changes. There was no significant relationship between baseline SUVmax or change in SUVmax with time on therapy. 18F-DCFPyL PET/CT suggested a more definitive estimate of baseline disease burden than standard imaging, although 2 men had non-18F-DCFPyL-avid sites of disease. Conclusions: 18F-DCFPyL PET/CT uncovers more sites of disease than standard imaging, although there is a sub-population of men with non-18F-DCFPyL-avid disease. The majority of disease sites demonstrate increasing 18F-DCFPyL following 9-14 weeks of therapy. A larger sample size is needed for confirmation.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".